Comparative Pharmacology
Head-to-head clinical analysis: KAPSPARGO SPRINKLE versus SPIRONOLACTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAPSPARGO SPRINKLE versus SPIRONOLACTONE.
KAPSPARGO SPRINKLE vs SPIRONOLACTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter-2 (SGLT2) inhibitor; reduces glucose reabsorption in renal proximal tubules, increasing urinary glucose excretion and lowering blood glucose.
Competitive antagonist of mineralocorticoid receptors in the distal convoluted tubule, inhibiting sodium reabsorption and potassium excretion; also has antiandrogenic activity by inhibiting androgen biosynthesis and blocking androgen receptors.
5 mg to 25 mg per day administered orally. For children below 80 kg, starting dose is 0.2 mg per kg per day. Maximum dose is 25 mg per day.
Oral: 25-200 mg daily in 1-2 divided doses for hypertension, heart failure, or cirrhosis with ascites. Maximum 400 mg/day.
None Documented
None Documented
Clinical Note
moderateSpironolactone + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Spironolactone."
Clinical Note
moderateSpironolactone + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Spironolactone."
Clinical Note
moderateSpironolactone + Acetyldigitoxin
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Spironolactone."
Clinical Note
moderateTerminal elimination half-life is 11-13 hours in healthy adults, 17-19 hours in elderly patients; clinically relevant for once-daily dosing.
Spironolactone: 1.4-2.5 hours; active metabolites: canrenone 16.5-22.5 hours, 7α-thiomethylspironolactone 10-15 hours. Clinical context: Metabolite half-lives determine dosing interval (once or twice daily).
Primarily renal excretion as unchanged drug (40-50%) and metabolites; fecal elimination accounts for <5%.
Renal: approximately 50% as metabolites (canrenone, 7α-thiomethylspironolactone) and unchanged drug; Biliary/Fecal: approximately 35% as metabolites; the remainder undergoes enterohepatic recirculation.
Category C
Category D/X
Aldosterone Antagonist
Aldosterone Antagonist
Spironolactone + Ouabain
"The therapeutic efficacy of Ouabain can be decreased when used in combination with Spironolactone."